G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups.
2. To determine the number of apheresis procedures, total stem cell yield/kg patient body
weight and the toxicity profile in the two groups.
Secondary Objectives:
1. To determine the degree of expression of various adhesion molecules in the 2 groups and
correlate with time to engraftment of neutrophils, platelets, and red blood cells,
efficacy of stem cell mobilization and purging.
2. To determine the incidence of disease progression/relapse at 12 months in the two
groups.